The latest cuts affect the company’s sales force and were not included in recent restructuring announcements that trimmed 3,500 research and development positions worldwide.
The pharmaceutical giant which has its North American headquarters in Wilmington will cut about 24% of its sales force in the United States. The company says the cuts will vary based on geography and selling teams.
“These are difficult decisions that impact valued employees,” said Rich Fante, president of AstraZeneca US in a statement. “The changes we are making, however, will help us deliver better results for our business and, most importantly, continue delivering on our mission of patient health.”
Employees will be able to “self-identify”, or volunteer to leave the company. All decisions on who stays and who is leaving will be made by February.
The sales force cut is the second step in the company’s restructuring effort that’s been underway since January 2010. Out of the 3,500 R&D cuts worldwide, more than 500 were targeted for the Wilmington facility.